Shares of Beigene Ltd (NASDAQ:BGNE) saw an uptick in trading volume on Friday . 51,512 shares changed hands during trading, a decline of 1% from the previous session’s volume of 52,232 shares.The stock last traded at $29.01 and had previously closed at $29.39.

Several research firms have recently weighed in on BGNE. Cowen and Company reiterated a “buy” rating on shares of Beigene in a report on Monday, June 6th. Morgan Stanley lifted their price objective on Beigene from $39.00 to $42.00 in a report on Friday, April 8th. Finally, Zacks Investment Research cut Beigene from a “hold” rating to a “sell” rating in a report on Monday, May 16th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $39.67.

The stock’s market cap is $668.14 million. The company’s 50 day moving average is $30.01 and its 200-day moving average is $28.99.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings results on Wednesday, May 11th. The company reported ($0.97) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.92. The company earned $0.70 million during the quarter. The company’s quarterly revenue was down 50.0% on a year-over-year basis. On average, equities analysts expect that Beigene Ltd will post ($3.17) earnings per share for the current fiscal year.

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.